Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 20;8(1):51.
doi: 10.1038/s41387-018-0059-4.

Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial

Simona Bo  1 , Roberto Gambino  2 , Valentina Ponzo  2 , Iolanda Cioffi  3 , Ilaria Goitre  2 , Andrea Evangelista  4 , Giovannino Ciccone  4 , Maurizio Cassader  2 , Massimo Procopio  2
Affiliations
Randomized Controlled Trial

Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial

Simona Bo et al. Nutr Diabetes. .

Abstract

Objectives: Patients with type 2 diabetes (T2DM) are at increased fracture risk. Resveratrol has shown beneficial effects on bone health in few studies. The aim of this trial was to investigate the effects of resveratrol on bone mineral density (BMD) and on calcium metabolism biomarkers in T2DM patients.

Methods: In this double-blind randomized placebo-controlled trial 192 T2DM outpatients were randomized to receive resveratrol 500 mg/day (Resv500 arm), resveratrol 40 mg/day (Resv40 arm) or placebo for 6 months. BMD, bone mineral content (BMC), serum calcium, phosphorus, alkaline phosphatase, and 25-hydroxy vitamin D were measured at baseline and after 6 months.

Results: At follow-up, calcium concentrations increased in all patients, while within-group variations in alkaline phosphatase were higher in both resveratrol arms, and 25-hydroxy vitamin D increased in the Resv500 arm only, without between-group differences. Whole-body BMD significantly decreased in the placebo group, while whole-body BMC decreased in both the placebo and Resv40 arms. No significant changes in BMD and BMC values occurred in the Resv500 arm. The adjusted mean differences of change from baseline were significantly different in the Resv500 arm vs placebo for whole-body BMD (0.01 vs -0.03 g/cm2, p = 0.001), whole-body BMC (4.04 vs -58.8 g, p < 0.001), whole-body T-score (0.15 vs -0.26), and serum phosphorus (0.07 vs -0.01 µmol/L, p = 0.002). In subgroup analyses, in Resv500 treated-patients BMD values increased to higher levels in those with lower calcium and 25-hydroxy vitamin D values, and in alcohol drinkers.

Conclusions: Supplementation with 500 mg resveratrol prevented bone density loss in patients with T2DM, in particular, in those with unfavorable conditions at baseline.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Adjusted mean difference on change from baseline (95% CI) of total BMD values (Resv500 arm vs Placebo arm)
Fig. 2
Fig. 2
Adjusted mean difference on change from baseline (95% CI) of total BMD values (Resv40 arm vs Placebo arm)
See this image and copyright information in PMC

References

    1. Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr. Osteoporos. Rep. 2015;13:186–191. doi: 10.1007/s11914-015-0265-0. - DOI - PubMed
    1. Carnevale D, Romagnoli E, D’Erasmo L, D’Erasmo E. Bone damage in type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2014;24:1151–1157. doi: 10.1016/j.numecd.2014.06.013. - DOI - PubMed
    1. Tomé-Carneiro J, et al. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharmac Des. 2013;19:6064–6093. doi: 10.2174/13816128113199990407. - DOI - PMC - PubMed
    1. Ponzo V, Soldati L, Bo S. Resveratrol: a supplementation for men or for mice? J. Transl. Med. 2014;12:158. doi: 10.1186/1479-5876-12-158. - DOI - PMC - PubMed
    1. Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R. Resveratrol supplementation: where are we now and where should we go? Ageing Res. Rev. 2015;21:1–15. doi: 10.1016/j.arr.2015.01.002. - DOI - PMC - PubMed

Publication types